Skip to main content

Core value dossiers for medical technologies

Essential tool to support market access and marketing efforts through the lifecycle of the product

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Reduction of reimbursement for the clinical laboratory by 15% in Belgium

27 Nov 2023

In November 2023, INAMI-RIZIV announced the budget reduction for reimbursement of clinical laboratory services by 15% from January 2024. INAMI-RIZIV estimates to free €223 million, which will be reallocated to other projects in health care. This change is part of the broader Hospital Reform.

Laboratories will be reimbursed at 85% of the current amount for the same services. INAMI-RIZIV considers this reimbursement sufficient, as analysis of accounting data shows a significant margin in clinical biology exams. If improved techniques allow health care to progress, it also makes it possible to reduce the cost of laboratory analyses. The reduction will not impact molecular biological and genetic testing.

See the full details here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.